Biotech Archives - Page 42 of 795

2 minute read

Ardelyx To Present Additional Data Supporting First-In-Class IBSRELA For Adults With Irritable Bowel Syndrome With Constipation At The 2024 Digestive Disease Week Conference

May 7, 8:13 AM

Ardelyx, Inc. (NASDAQ:ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that

ARDX

1 minute read

Alimera Announces Scientific Data Highlighting YUTIQ To Be Presented At Upcoming Association For Research In Vision And Ophthalmology And Retina World Congress Conferences

By Benzinga Newsdesk

May 7, 8:11 AM

Alimera Sciences, Inc. (NASDAQ:ALIM) ("Alimera"), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer,

ALIM

2 minute read

Aspira Women’s Health Announces Publication Of Two OvaWatch Peer-Reviewed Manuscripts

By Benzinga Newsdesk

May 7, 8:10 AM

Aspira Women's Health Inc. ("Aspira" or the "Company") (NASDAQ:AWH), a bio-analytical based women's health company focused on the development of gynecologic disease diagnostic tools, today announced the publication of

AWH

3 minute read

Traws Pharma Completes First Cohort Dosed In Phase 1 Trial For COVID Therapy

By Benzinga Newsdesk

May 7, 8:09 AM

Investigational travatrelvir demonstrated preclinical activity against multiple SARS-CoV-2 variants Orally administered novel protease inhibitor does not require ritonavir co-administrationFirst-in-Human study to

TRAW

1 minute read

Sagimet Announces Oral Presentation Of Data From The Phase 2b FASCINATE-2 Study Of Denifanstat In MASH At EASL International Liver Congress 2024

By Benzinga Newsdesk

May 7, 8:05 AM

Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today

SGMT

2 minute read

Eterna Therapeutics To Present at The ASGCT 27th Annual Meeting On Development Of Beta 2 Microglobulin-Knockout iMSC Line With Enhanced Immunosuppressive Activity And Stealthing Features That May Further Augment The Therapeutic Potential Of MSCs In Inf…

By Benzinga Newsdesk

May 7, 8:04 AM

The presentation reports the development of a beta 2 microglobulin-knockout (B2M-KO) iMSC line with enhanced immunosuppressive activity and stealthing features that may further augment the therapeutic potential of MSCs

ERNA

1 minute read

Matinas BioPharma’s LNC Platform For The Delivery Of Small Oligonucleotides Featured In Two Presentations At The ASGCT Annual Meeting

By Benzinga Newsdesk

May 7, 8:04 AM

Matinas BioPharma Holdings, Inc. (NYSE:MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology, announces that James

MTNB

2 minute read

Profound Medical Says Growing Body Of Clinical Evidence Points To The Potential Of TULSA Procedure Becoming A Mainstream Treatment Modality Across The Entire Prostate Disease Spectrum

By Benzinga Newsdesk

May 6, 4:45 PM

— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA

PROF

4 minute read

Veracyte Announces Data From 14 Studies Presented At AUA 2024 Show Decipher Tests’ Ability To Help Personalize Care For Prostate And Bladder Cancer Patients And Advance Disease Understanding

By Benzinga Newsdesk

May 6, 4:30 PM

Large number of abstracts also showcases power of the Veracyte Diagnostics PlatformVeracyte, Inc. (NASDAQ:VCYT), a leading cancer diagnostics company, today announced that data from 14 presentations at AUA 2024, the

VCYT

2 minute read

Merus Announces U.S. FDA Acceptance And Priority Review Of BLA For Zeno For The Treatment Of NRG1+ NSCLC And PDAC

By Benzinga Newsdesk

May 6, 4:28 PM

Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the

MRUS